Number of centres planned : 16 centres in France Type of study / Study design : Research Involving the Human Person category 2. Multicentric. Prospective Planning of the study : Total duration: 57,5 months. Recruitment period: 33.5 months. Follow-up time per patients : 2 years Expected number of cases : The study will involve a maximum of 900 individuals, from 16 centers in France300 family trios (consisting of 150 index cases and their 2 parents, healthy volunteers, N= 450 individuals) \- In the event of unavailability, refusal, non-compliance with an inclusion or exclusion criterion concerning one of the biological parents, only the index case (patient) will be included in the study without his or her parents. The 300 index cases with ventriculo-arterial discordance will be divided into two groups: 100 double discordance cases and 200 large-vessel transpositions. These group inclusion targets are theoretical. If the proportion of patients available for inclusion turns out to be higher than expected for one of the groups, the targets may be adjusted, while maintaining a maximum of 300 cases included (corresponding to 900 subjects if all trios are complete). Patients and their parents will be informed of the study by their referring cardiologist, and their written consent will be obtained. Translated with DeepL.com (free version) Treatment, procedure, combination of procedures under consideration : * Blood samples for genetic analyses collected at the inclusion visit for patients and parents in case of trio families Schedule of different visits and examinations : Inclusion visit: * Collection of demographic, clinical data from the index case and parents * DNA sampling for genetic research (biocollection) of the index case or family trio * Completion of the quality of life questionnaire Annual visit with a 2 years follow-up: * Retrieval of data from the index case * Completion of the quality of life questionnaire
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
600
Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
CHU Marseille
Marseille, Bouches-du-Rhône, France
CHU Rennes
Rennes, Brittany Region, France
CHU Bordeaux
Bordeaux, Gironde, France
CHU Toulouse
Toulouse, Haute-Garonne, France
CHU de Lille
Lille, Hauts-de-France, France
Groupe Hospitalier St Joseph - Hôpital Marie Lannelongue
Le Plessis-Robinson, Hauts-de-Seine, France
CHU Nantes
Nantes, Loire-Atlantique, France
Hôpital Nord Laennec
Saint-Herblain, Loire-Atlantique, France
CHU Angers
Angers, Maine-et-Loire, France
CHU Nancy
Nancy, Meurthe-et-Moselle, France
...and 6 more locations
Identification new genes/variants involved in congenital heart disease with transposition congenitally corrected of the great arteries, based on whole genome sequencing of familial trios.
Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
Time frame: 24 months
Evaluation the diagnostic contribution of parental cardiovascular screening in case of ventriculo-arterial discordance (transposition of the great arteries, transposition congenitally corrected of the great arteries) in the index case.
Evolution of diagnostic performance for congenital heart disease in relatives of the index case with ventriculo-arterial discordance following the introduction of parental screening.
Time frame: 24 months
Identification new familial forms of ventriculo-arterial discordance.
Identification of genotype/phenotype relationships by studying associations between clinical features and identified genetic variants.
Time frame: 24 months
Identification epigenetic modifications by analysis of the epigenome of sporadic forms when genome sequencing is not contributory.
Detection of epigenetic modifications.
Time frame: 24 months
Identification allelic variants associated with prognosis and/or response to treatment, with the aim of eventually developing a precision medicine programme in paediatric cardiology
Identification of genotype/phenotype relationships in relation to prognosis and/or response to treatment
Time frame: 2 years
Assessing the quality of life of patients with ventriculo-arterial discordance as well as their parents
To document quality of life longitudinally in this patient population using Pediatric Quality of Life InventoryTM (scale from 0 to 4 ; 4 being the worst outcome)
Time frame: 2 years
Assessing the quality of life of patients with ventriculo-arterial discordance as well as their parents
To document quality of life longitudinally in this patient population using The Short Form (36) Health Survey (scale from 1 to 6 ; 6 being the worst outcome)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.